Objective: To explore the value of CT guided radiofrequency ablation (RFA) in treatment of post-operational resectable liver metastatic tumors from colorectal carcinoma.
Methods: Thirty-seven patients with 52 resectable liver metastatic tumors from colorectal carcinoma underwent CT guided RFA. CT, MRI, ultrasonography, and/or PET/CT were conducted after RFA every 2 months. Results of this study were compared with data from literatures about surgical resection applied in liver metastases from colorectal carcinoma.
Results: Abdominal bleeding and abdominal infection occurred in 1 patient respectively (2.7%, 1/37). No treatment-induced death occurred. The total complication rate was 5.4%. The median survival time of the patients treated by RFA was 39.8 months. The 3-year survival rate was 42.6%.
Conclusion: With the clinical value similar to that of surgical resection, CT guided RFA can be one of the first choices for post-operational resectable liver metastatic tumors from colorectal carcinoma thanks to minimal invasion and low complication rate.
Download full-text PDF |
Source |
---|
Surgery
January 2025
Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Hepatobiliary & General Surgery, IRCCS Humanitas Research Hospital, Milan, Italy. Electronic address:
Background: Communicating vessels among hepatic veins in patients with tumors invading/compressing hepatic veins at their caval confluence facilitate new surgical solutions. Although their recognition by intraoperative ultrasound has been described, the possibility of preoperative detection still remains uncertain. We aimed to develop a model to predict their presence before surgery.
View Article and Find Full Text PDFPancreas
January 2025
Department of Surgery, Division of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, the Netherlands.
Objectives: A significant proportion of patients undergoing surgery for pancreatic ductal adenocarcinoma (PDAC) are anemic at the time of resection. In these patients, blood transfusions are omitted due to their potential negative impact on oncological outcomes. The aim of the present study was to determine the prognostic value of preoperative anemia in resected PDAC patients, irrespective of blood transfusion status.
View Article and Find Full Text PDFCurr Issues Mol Biol
January 2025
Division of Interventional and Surgical Science, Royal Free Campus, University College London, London NW3 2QG, UK.
Liver ischaemia-reperfusion (IR) injury remains a major cause of morbidity and mortality following liver transplantation and resection. CD4+ T cells have been shown to play a key role in murine models; however, there is currently a lack of data that support their role in human patients. Data on clinical outcomes and complications were documented prospectively in 28 patients undergoing first elective liver transplant surgery.
View Article and Find Full Text PDFSurg Endosc
January 2025
Division of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Background: Both laparoscopic hepatectomy (LH) and robotic hepatectomy (RH) have been performed for tumors in nearly all liver segments. However, few studies have compared the outcomes of patients who underwent open hepatectomy (OH), LH and RH for the treatment of Barcelona Clinic Liver Cancer (BCLC) stage 0-A HCC in S7/8.
Methods: The clinical data of patients who underwent S7/8 resection for the treatment of BCLC stage 0-A HCC in the First Affiliated Hospital of Guangxi Medical University from July 2017 to July 2023 were retrospectively collected.
Acad Radiol
January 2025
Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China (Q.L., J.O., Y.Z., J.Z.). Electronic address:
Rationale And Objectives: The purpose of this study was to demonstrate the impact of postoperative adjuvant transarterial chemoembolization (TACE) on the prognosis of patients with macrotrabecular-massive hepatocellular carcinoma (MTM-HCC).
Materials And Methods: This retrospective study used the clinical records of patients with resected MTM-HCC with/without adjuvant TACE at three centers between January 2015 and December 2022. The primary end point was recurrence free survival (RFS).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!